Last reviewed 2026-05-28 · How we verify

TGFbeta resistant LMP-specific CTLs

Baylor College of Medicine · Phase 1 active Biologic ✓ Verified May 2026

TGFbeta resistant LMP-specific CTLs is a Biologic drug developed by Baylor College of Medicine. It is currently in Phase 1 development. Also known as: TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes.

Researchers at Baylor College of Medicine are studying the use of TGFbeta resistant LMP-specific CTLs in treating lymphoma, including Hodgkin's disease and non-Hodgkin lymphoma, particularly in cases of relapse. This treatment involves administering autologous or allogeneic TGFbeta-resistant LMP-specific CTLs to patients.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TGFbeta resistant LMP-specific CTLs
Also known as	TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes
Sponsor	Baylor College of Medicine
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TGFbeta resistant LMP-specific CTLs CI brief — competitive landscape report
TGFbeta resistant LMP-specific CTLs updates RSS · CI watch RSS
Baylor College of Medicine portfolio CI

Frequently asked questions about TGFbeta resistant LMP-specific CTLs

What is TGFbeta resistant LMP-specific CTLs?

TGFbeta resistant LMP-specific CTLs is a Biologic drug developed by Baylor College of Medicine.

Who makes TGFbeta resistant LMP-specific CTLs?

TGFbeta resistant LMP-specific CTLs is developed by Baylor College of Medicine (see full Baylor College of Medicine pipeline at /company/baylor-college-of-medicine).

Is TGFbeta resistant LMP-specific CTLs also known as anything else?

TGFbeta resistant LMP-specific CTLs is also known as TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes.

What development phase is TGFbeta resistant LMP-specific CTLs in?

TGFbeta resistant LMP-specific CTLs is in Phase 1.

Manufacturer: Baylor College of Medicine — full pipeline
Also known as: TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing